Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: A post hoc analysis

Full text
Show less -
Hernandez, Mariel J. [1, 2] ; dos Reis, Luciene M. [1] ; Marques, Igor D. [1] ; Araujo, Maria J. [1, 3] ; Truyts, Cesar A. M. [1] ; Oliveira, Ivone B. [1] ; Barreto, Fellype C. [4] ; David-Neto, Elias [3] ; Custodio, Melani R. [1] ; Moyses, Rosa M. [5, 1] ; Bellorin-Font, Ezequiel [2] ; Jorgetti, Vanda [1, 6]
Total Authors: 12
[1] Univ Sao Paulo, Hosp Clin HCFMUSP, LIM Lab Fisiopatol Renal 16, Fac Med, Sao Paulo, SP - Brazil
[2] Univ Cent Venezuela, Hosp Univ Caracas, Serv Nefrol & Trasplante Renal, Caracas - Venezuela
[3] Univ Sao Paulo, Div Urol, HCFMUSP, Hosp Clin, Fac Med, Sao Paulo, SP - Brazil
[4] Univ Fed Parana, Div Nefrol, Curitiba, Parana - Brazil
[5] Univ Nove Julho UNINOVE, Programa Posgrad Med, Sao Paulo, SP - Brazil
[6] Hosp Samaritano Amer Serv Med, Sao Paulo, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: PLoS One; v. 13, n. 5 MAY 25 2018.
Web of Science Citations: 0

Purpose Osteoblasts and adipocytes are derived from mesenchymal stem cells. An imbalance in the differentiation of these lineages could affect the preservation of bone integrity. Several studies have suggested the importance of this imbalance in the pathogenesis of osteoporosis after kidney transplant (KT), but the role of bone marrow adiposity in this process is not well known, and if the treatment with the anti-absorptive (zoledronic acid-ZA) drugs could attenuate bone loss. Thus, our objective was compare bone marrow adiposity, osteoblasts and osteocytes before and after KT, verify an association between bone remodeling process (Turnover, Volume, and Mineralization-TMV classification), the osteocyte sclerostin expression to evaluate if there is a role of Wnt pathway, as well as the effect of ZA on these cells. Methods We studied 29 new living-adonor KT patients. One group received ZA at the time of KT plus cholecalciferol for twelve months, and the other group received only cholecalciferol. Bone biopsies were performed at baseline and after 12 months of treatment. Histomorphometric evaluation was performed in bone and bone marrow adipocytes. Sclerostin (Scl) expression in osteocytes was evaluated by immunohistochemistry. Results Some bone marrow adiposity parameters were increased before KT. After KT, some of them remained increased and they worsened with the use of ZA. In the baseline, lower bone Volume and Turnover, were associated with increased bone marrow adiposity parameters (some of them). After KT, both groups showed the same associations. Osteocyte Scl expression after KT decreased with the use of ZA. We observed also an inverse association between bone adiposity parameters and lower osteocyte sclerostin expression 12 months after KT. Conclusion In conclusion, the present study suggests that KT fails to normalize bone marrow adiposity, and it even gets worse with the use of ZA. Moreover, bone marrow adiposity is inversely associated with bone Volume and Turnover, which seems to be accentuated by the antiresorptive therapy. (AU)

FAPESP's process: 11/22962-3 - A prospective and randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation
Grantee:Elias David-Neto
Support type: Regular Research Grants